COPD is a chronic inflammatory condition that limits airflow ... Despite the benefits of Ohtuvayre, the treatment is pricey, ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

2010;67(13):1061-1069. Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations. The data of deJong et al. [30] showed no ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis ... entirely new direction for potential treatment of IPF," said lead author Santu ...

Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

Performed for the first time ever at the nationally significant hospital "San Pio" in Benevento, led by general director ...

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

COPD is a progressive lung disease that makes breathing difficult. There is no cure, but treatments can help manage symptoms and improve quality of life for patients. ILD refers to a group of ...